Treatment of @entity1103 secondary to chronic non-infectious intermediate XXXX with an intraocular @entity619 implant.

@entity1 @entity32 @entity1596 @entity1103 @entity4932 @entity619 @entity2038 @entity230
PURPOSE: To evaluate the use of a slow-release @entity619 0.7-mg intravitreal implant for @entity1103 ( @entity1103 ) secondary to intermediate @entity1596 and refractory to systemic @entity230 . METHODS: A retrospective study of the best-corrected visual acuity (BCVA), @entity32 , intraocular pressure (IOP), fundus photography, optical coherence tomography (OCT), @entity32 , and adverse reactions of five @entity1 ( @entity1 , mean age of 35 years) with @entity1103 treated with a @entity619 implant. @entity1 were evaluated in seven visits until the 150th day after the implant. RESULTS: Four @entity1 had bilateral pars @entity2038 and one had bilateral intermediate @entity1596 associated with @entity4932 . Six @entity619 devices were implanted, under topical anesthesia (one each in six eyes, five @entity1 ). The mean follow-up time was 5 months. The best-corrected visual acuity improved in all eyes that received an implant, with five having improvements of two or more lines. Optical coherence tomography showed thinning of the macula in all eyes treated, and we saw a correlation between the best-corrected visual acuity and retinal thinning. No serious adverse events occurred and no significant increase in intraocular pressure was observed. CONCLUSIONS: Slow-release @entity619 intravitreal implants can effectively treat @entity1103 secondary to intermediate @entity1596 and refractory to systemic @entity230 .
